Symbols / RLYB
RLYB Chart
About
Rallybio Corporation, a clinical-stage biotechnology company, engages in development and commercialization of life-transforming therapies for patients suffering from severe and rare diseases. Its lead product candidate is RLYB212, a monoclonal anti-HPA-1a antibody which is in Phase II clinical trial for the prevention of fetal and neonatal alloimmune thrombocytopenia (FNAIT); and RLYB211 for the prevention of FNAIT. The company is also developing RLYB114, a pegylated complement factor 5 (C5)-targeted Affibody molecule in preclinical development for the treatment of complement-mediated ophthalmic diseases; RLYB116, an inhibitor of complement component 5 (C5) to treat several diseases of complement dysregulation which has completed phase 1 trial; and RLYB332, a preclinical antibody, for the treatment of severe anemia with ineffective erythropoiesis and iron overload. It entered into a strategic alliance with AbCellera to discover, develop, and commercialize novel antibody-based therapeutics for rare diseases. Rallybio has collaboration with Exscientia for the development of small molecule therapeutics for rare diseases; and collaboration agreement with Johnson & Johnson to provide pregnant individuals therapeutic solutions at risk of fetal and neonatal alloimmune thrombocytopenia. The company was founded in 2018 and is headquartered in New Haven, Connecticut.
Fundamentals
Scroll to Statements| Sector | Healthcare | Industry | Biotechnology | Market Cap | 32.00M |
| Enterprise Value | -28.34M | Income | -14.17M | Sales | 674.00K |
| Book/sh | 12.03 | Cash/sh | 11.23 | Dividend Yield | — |
| Payout | 0.00% | Employees | 15 | IPO | — |
| P/E | — | Forward P/E | -0.60 | PEG | — |
| P/S | 47.48 | P/B | 0.50 | P/C | — |
| EV/EBITDA | 0.85 | EV/Sales | -42.04 | Quick Ratio | 13.13 |
| Current Ratio | 14.74 | Debt/Eq | 0.31 | LT Debt/Eq | — |
| EPS (ttm) | -2.56 | EPS next Y | -10.08 | EPS Growth | — |
| Revenue Growth | -29.10% | Earnings | 2025-11-06 08:00 | ROA | -28.35% |
| ROE | -21.17% | ROIC | — | Gross Margin | 0.00% |
| Oper. Margin | -32.67% | Profit Margin | 0.00% | Shs Outstand | 5.28M |
| Shs Float | 2.54M | Short Float | 0.35% | Short Ratio | 0.97 |
| Short Interest | — | 52W High | 6.40 | 52W Low | 1.76 |
| Beta | -1.05 | Avg Volume | 27.02K | Volume | 111.06K |
| Target Price | $8.00 | Recom | Buy | Prev Close | $5.83 |
| Price | $6.06 | Change | 3.95% |
Valuation Models
Price estimates from analyst targets and simple models.
1. Analyst consensus
$8.00
Mean price target
2. Current target
$6.06
Latest analyst target
3. DCF / Fair value
$-74.70
Simplified: (Free Cash Flow ÷ Shares) × 18 (P/FCF multiple). Not a …
Ratings
Current target
$6.06
Low
$8.00
High
$8.00
Mean
$8.00
Latest analyst rating changes
| Date | Action | Analyst | Rating Change | Price Target |
|---|---|---|---|---|
| 2025-04-15 | down | Jones Trading | Buy → Hold | — |
| 2025-04-09 | down | HC Wainwright & Co. | Buy → Neutral | — |
| 2025-03-17 | reit | HC Wainwright & Co. | Buy → Buy | $5 |
| 2025-02-12 | reit | HC Wainwright & Co. | Buy → Buy | $5 |
| 2025-01-13 | reit | HC Wainwright & Co. | Buy → Buy | $5 |
| 2024-12-03 | reit | HC Wainwright & Co. | Buy → Buy | $5 |
| 2024-11-22 | reit | HC Wainwright & Co. | Buy → Buy | $5 |
| 2024-11-08 | main | HC Wainwright & Co. | Buy → Buy | $5 |
| 2024-10-30 | reit | HC Wainwright & Co. | Buy → Buy | $6 |
| 2024-10-01 | reit | HC Wainwright & Co. | Buy → Buy | $6 |
| 2024-09-03 | reit | HC Wainwright & Co. | Buy → Buy | $6 |
| 2024-08-26 | main | Evercore ISI Group | Outperform → Outperform | $15 |
| 2024-08-12 | main | HC Wainwright & Co. | Buy → Buy | $6 |
| 2024-05-15 | down | JP Morgan | Overweight → Neutral | — |
| 2024-05-10 | reit | HC Wainwright & Co. | Buy → Buy | $9 |
| 2024-04-19 | reit | JMP Securities | Market Outperform → Market Outperform | $8 |
| 2024-04-18 | reit | JMP Securities | Market Outperform → Market Outperform | $8 |
| 2024-04-11 | main | Wedbush | Outperform → Outperform | $11 |
| 2024-03-13 | reit | JMP Securities | Market Outperform → Market Outperform | $8 |
| 2024-03-13 | main | HC Wainwright & Co. | Buy → Buy | $9 |
- Rallybio (RLYB) Price Target Increased by 700.00% to 8.16 - Nasdaq Wed, 25 Feb 2026 01
- Rallybio (NASDAQ: RLYB) director granted options in lieu of cash - Stock Titan Fri, 20 Feb 2026 22
- Rallybio Announces Reverse Stock Split of Common Stock - Business Wire ue, 03 Feb 2026 08
- Lieber, Rallybio CFO, sells $3992 in shares - Investing.com ue, 24 Feb 2026 04
- Rallybio Shares Successful Early-Stage Results for Rare Disease Drug; New Trial Set for Late 2026 - Benzinga ue, 17 Feb 2026 15
- Market Movers | Winners: ADIL, ASST, RLYB | Losers: OBAI, GEOS, PFSA - Trefis hu, 05 Feb 2026 08
- We're Keeping An Eye On Rallybio's (NASDAQ:RLYB) Cash Burn Rate - simplywall.st hu, 10 Jul 2025 07
- Rallybio stock climbs on deal with Recursion (RLYB:NASDAQ) - Seeking Alpha ue, 08 Jul 2025 07
- Weekly Rallybio shot fully shuts down terminal complement in early trial - Stock Titan ue, 17 Feb 2026 13
- Rallybio To Implement 1 For 8 Reverse Stock Split To Regain Nasdaq Compliance;Stock Down - Nasdaq Wed, 04 Feb 2026 08
- Rallybio Announces Reverse Stock Split Of Common Stock - TradingView ue, 03 Feb 2026 08
- Market Movers | Winners: ASST, ADIL, RLYB | Losers: EAF, ERNA, ANEB - Trefis Sat, 07 Feb 2026 04
- Rallybio to implement 1-for-8 reverse stock split effective February 6 - Investing.com hu, 29 Jan 2026 08
- Rallybio's $25M REV102 Sale to Recursion Promises First Oral Treatment for Rare Bone Disease - Stock Titan ue, 08 Jul 2025 07
- After-Hours Biotech Watch: IFRX, ABCL, RLYB Among Notable Risers - Nasdaq Sun, 09 Nov 2025 08
Insider Transactions
No recent insider transactions.
Financials
| Line Item | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 |
|---|---|---|---|---|
| TaxEffectOfUnusualItems | 0.00 | 0.00 | 0.00 | 0.00 |
| TaxRateForCalcs | 0.00 | 0.00 | 0.00 | 0.00 |
| NormalizedEBITDA | -60.37M | -78.78M | -67.72M | -45.39M |
| NetIncomeFromContinuingOperationNetMinorityInterest | -57.77M | -74.56M | -66.65M | -47.01M |
| ReconciledDepreciation | 131.00K | 150.00K | 167.00K | 109.00K |
| EBITDA | -60.37M | -78.78M | -67.72M | -45.39M |
| EBIT | -60.50M | -78.93M | -67.88M | -45.50M |
| NetInterestIncome | 4.22M | 6.15M | 1.96M | 44.00K |
| InterestExpense | 0.00 | 10.00K | ||
| InterestIncome | 4.22M | 6.15M | 1.96M | 54.00K |
| NormalizedIncome | -57.77M | -74.56M | -66.65M | -47.01M |
| NetIncomeFromContinuingAndDiscontinuedOperation | -57.77M | -74.56M | -66.65M | -47.01M |
| TotalExpenses | 61.13M | 78.93M | 67.88M | 45.65M |
| TotalOperatingIncomeAsReported | -60.50M | -78.93M | -67.88M | -45.65M |
| DilutedAverageShares | 5.44M | 5.06M | 3.98M | 3.19M |
| BasicAverageShares | 5.44M | 5.06M | 3.98M | 3.19M |
| DilutedEPS | -10.64 | -14.72 | -16.72 | -14.72 |
| BasicEPS | -10.64 | -14.72 | -16.72 | -14.72 |
| DilutedNIAvailtoComStockholders | -57.77M | -74.56M | -66.65M | -47.01M |
| NetIncomeCommonStockholders | -57.77M | -74.56M | -66.65M | -47.01M |
| NetIncome | -57.77M | -74.56M | -66.65M | -47.01M |
| NetIncomeIncludingNoncontrollingInterests | -57.77M | -74.56M | -66.65M | -47.01M |
| NetIncomeContinuousOperations | -57.77M | -74.56M | -66.65M | -47.01M |
| EarningsFromEquityInterestNetOfTax | -1.07M | -1.50M | ||
| TaxProvision | 0.00 | |||
| PretaxIncome | -57.77M | -74.56M | -66.65M | -45.51M |
| OtherIncomeExpense | -1.50M | -1.78M | -733.00K | 96.00K |
| OtherNonOperatingIncomeExpenses | 744.00K | 262.00K | 342.00K | 96.00K |
| EarningsFromEquityInterest | -2.24M | -2.04M | -1.07M | |
| NetNonOperatingInterestIncomeExpense | 4.22M | 6.15M | 1.96M | 44.00K |
| InterestExpenseNonOperating | 0.00 | 10.00K | ||
| InterestIncomeNonOperating | 4.22M | 6.15M | 1.96M | 54.00K |
| OperatingIncome | -60.50M | -78.93M | -67.88M | -45.65M |
| OperatingExpense | 61.13M | 78.93M | 67.88M | 45.65M |
| ResearchAndDevelopment | 41.51M | 53.54M | 40.69M | 26.91M |
| SellingGeneralAndAdministration | 19.62M | 25.39M | 27.20M | 18.74M |
| GeneralAndAdministrativeExpense | 19.62M | 25.39M | 27.20M | 18.74M |
| OtherGandA | 19.62M | 25.39M | 27.20M | 18.74M |
| TotalRevenue | 636.00K | 0.00 | 0.00 | 0.00 |
| OperatingRevenue | 636.00K | 0.00 | 0.00 | 0.00 |
| Line Item | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 |
|---|---|---|---|---|
| OrdinarySharesNumber | 5.19M | 4.73M | 4.73M | 4.02M |
| ShareIssued | 5.19M | 4.73M | 4.73M | 4.02M |
| TotalDebt | 154.00K | 392.00K | 555.00K | 0.00 |
| TangibleBookValue | 61.65M | 106.18M | 169.32M | 175.60M |
| InvestedCapital | 61.65M | 106.18M | 169.32M | 175.60M |
| WorkingCapital | 61.60M | 105.53M | 168.75M | 174.32M |
| NetTangibleAssets | 61.65M | 106.18M | 169.32M | 175.60M |
| CapitalLeaseObligations | 154.00K | 392.00K | 555.00K | 0.00 |
| CommonStockEquity | 61.65M | 106.18M | 169.32M | 175.60M |
| TotalCapitalization | 61.65M | 106.18M | 169.32M | 175.60M |
| TotalEquityGrossMinorityInterest | 61.65M | 106.18M | 169.32M | 175.60M |
| StockholdersEquity | 61.65M | 106.18M | 169.32M | 175.60M |
| GainsLossesNotAffectingRetainedEarnings | 68.00K | 15.00K | -214.00K | 0.00 |
| OtherEquityAdjustments | 68.00K | 15.00K | -214.00K | |
| RetainedEarnings | -293.02M | -235.25M | -160.68M | -94.03M |
| AdditionalPaidInCapital | 354.60M | 341.41M | 330.21M | 269.63M |
| CapitalStock | 4.00K | 4.00K | 4.00K | 3.00K |
| CommonStock | 4.00K | 4.00K | 4.00K | 3.00K |
| PreferredStock | 0.00 | 0.00 | 0.00 | 0.00 |
| TotalLiabilitiesNetMinorityInterest | 6.45M | 9.44M | 11.12M | 6.58M |
| TotalNonCurrentLiabilitiesNetMinorityInterest | 212.00K | 173.00K | 374.00K | 32.00K |
| NonCurrentAccruedExpenses | 0.00 | 32.00K | ||
| NonCurrentDeferredLiabilities | 212.00K | 0.00 | ||
| NonCurrentDeferredRevenue | 212.00K | 0.00 | ||
| LongTermDebtAndCapitalLeaseObligation | 0.00 | 173.00K | 374.00K | 0.00 |
| LongTermCapitalLeaseObligation | 0.00 | 173.00K | 374.00K | 0.00 |
| CurrentLiabilities | 6.24M | 9.26M | 10.74M | 6.55M |
| CurrentDeferredLiabilities | 848.00K | 0.00 | ||
| CurrentDeferredRevenue | 848.00K | 0.00 | ||
| CurrentDebtAndCapitalLeaseObligation | 154.00K | 219.00K | 181.00K | |
| CurrentCapitalLeaseObligation | 154.00K | 219.00K | 181.00K | 0.00 |
| PensionandOtherPostRetirementBenefitPlansCurrent | 3.10M | 3.17M | 4.70M | 2.96M |
| PayablesAndAccruedExpenses | 2.15M | 5.88M | 5.86M | 3.60M |
| CurrentAccruedExpenses | 1.87M | 4.90M | 4.75M | 2.99M |
| Payables | 278.00K | 976.00K | 1.11M | 603.00K |
| AccountsPayable | 278.00K | 976.00K | 1.11M | 603.00K |
| TotalAssets | 68.11M | 115.62M | 180.44M | 182.19M |
| TotalNonCurrentAssets | 267.00K | 831.00K | 939.00K | 1.32M |
| InvestmentsAndAdvances | 0.00 | 239.00K | 30.00K | 805.00K |
| LongTermEquityInvestment | 0.00 | 239.00K | 30.00K | 805.00K |
| InvestmentsinJointVenturesatCost | 0.00 | 239.00K | 30.00K | 805.00K |
| NetPPE | 267.00K | 592.00K | 909.00K | 511.00K |
| AccumulatedDepreciation | -654.00K | -523.00K | -373.00K | -206.00K |
| GrossPPE | 921.00K | 1.11M | 1.28M | 717.00K |
| Leases | 338.00K | 338.00K | 338.00K | 315.00K |
| ConstructionInProgress | 0.00 | 8.00K | ||
| OtherProperties | 524.00K | |||
| MachineryFurnitureEquipment | 431.00K | 431.00K | 420.00K | 394.00K |
| BuildingsAndImprovements | 152.00K | 346.00K | 524.00K | |
| Properties | 0.00 | 0.00 | 0.00 | 0.00 |
| CurrentAssets | 67.84M | 114.79M | 179.50M | 180.87M |
| OtherCurrentAssets | 995.00K | 2.05M | 1.05M | 395.00K |
| PrepaidAssets | 1.33M | 2.81M | 9.45M | 5.14M |
| CashCashEquivalentsAndShortTermInvestments | 65.51M | 109.93M | 168.99M | 175.33M |
| OtherShortTermInvestments | 51.61M | 85.44M | 112.04M | 0.00 |
| CashAndCashEquivalents | 13.90M | 24.49M | 56.96M | 175.33M |
| Line Item | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 |
|---|---|---|---|---|
| FreeCashFlow | -49.28M | -60.28M | -57.34M | -45.87M |
| IssuanceOfCapitalStock | 5.41M | 0.00 | 51.53M | 86.20M |
| CapitalExpenditure | -12.00K | -54.00K | -333.00K | |
| EndCashPosition | 13.90M | 24.49M | 56.96M | 175.33M |
| BeginningCashPosition | 24.49M | 56.96M | 175.33M | 140.23M |
| ChangesInCash | -10.59M | -32.46M | -118.38M | 35.10M |
| FinancingCashFlow | 5.20M | 143.00K | 51.08M | 82.97M |
| CashFlowFromContinuingFinancingActivities | 5.20M | 143.00K | 51.08M | 82.97M |
| NetOtherFinancingCharges | -268.00K | -139.00K | -693.00K | -3.23M |
| ProceedsFromStockOptionExercised | 62.00K | 282.00K | 238.00K | 0.00 |
| NetCommonStockIssuance | 5.41M | 0.00 | 51.53M | 86.20M |
| CommonStockIssuance | 5.41M | 0.00 | 51.53M | 86.20M |
| InvestingCashFlow | 33.49M | 27.66M | -112.17M | -2.33M |
| CashFlowFromContinuingInvestingActivities | 33.49M | 27.66M | -112.17M | -2.33M |
| NetInvestmentPurchaseAndSale | 35.49M | 29.92M | -111.82M | 0.00 |
| SaleOfInvestment | 84.42M | 138.33M | 89.50M | 0.00 |
| PurchaseOfInvestment | -48.93M | -108.41M | -201.32M | 0.00 |
| NetBusinessPurchaseAndSale | -2.00M | -2.25M | -300.00K | -2.00M |
| PurchaseOfBusiness | -2.00M | -2.25M | -300.00K | -2.00M |
| NetPPEPurchaseAndSale | 0.00 | -12.00K | -54.00K | -333.00K |
| PurchaseOfPPE | 0.00 | -12.00K | -54.00K | -333.00K |
| OperatingCashFlow | -49.28M | -60.27M | -57.28M | -45.53M |
| CashFlowFromContinuingOperatingActivities | -49.28M | -60.27M | -57.28M | -45.53M |
| ChangeInWorkingCapital | -258.00K | 4.28M | -936.00K | -3.78M |
| ChangeInOtherWorkingCapital | 1.06M | |||
| ChangeInPayablesAndAccruedExpense | -4.04M | -1.54M | 3.71M | 728.00K |
| ChangeInAccruedExpense | -3.34M | -1.44M | 3.22M | 1.70M |
| ChangeInPayable | -698.00K | -99.00K | 487.00K | -976.00K |
| ChangeInAccountPayable | -698.00K | -99.00K | 487.00K | -976.00K |
| ChangeInPrepaidAssets | 2.72M | 5.82M | -4.64M | -4.51M |
| OtherNonCashItems | -1.61M | -3.09M | -435.00K | |
| StockBasedCompensation | 7.99M | 10.92M | 9.50M | 3.65M |
| DepreciationAmortizationDepletion | 131.00K | 150.00K | 167.00K | 109.00K |
| DepreciationAndAmortization | 131.00K | 150.00K | 167.00K | 109.00K |
| OperatingGainsLosses | 2.24M | 2.04M | 1.07M | 1.50M |
| EarningsLossesFromEquityInvestments | 2.24M | 2.04M | 1.07M | 1.50M |
| NetIncomeFromContinuingOperations | -57.77M | -74.56M | -66.65M | -47.01M |
SEC Filings
Recent 10-K, 10-Q, 8-K, and Form 4 (insider) filings.
Public Trades for RLYB
| Date | User | Asset | Broker | Type | Position Size | Entry Price | Patterns |
|---|